At JP Morgan Week 2025, pharmaphorum’s Jonah Comstock took a quick detour to Grove.AI’s San Francisco offices to talk to ...

The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...

Digital tools, powered by intuitive design, AI, and customer centricity, offer a unique opportunity to bridge the trust gap ...

Artificial intelligence startup Quibim has raised $50 million in first-round financing to support the rollout of its ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Over 6.3 million patients make up the NHS backlog for consultant-led elective care, which reached 7,573,212 in September 2024 ...

Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary ...

2025 is going to be a year of great change. At a macro level, political and geopolitical shifts around the world will reshape ...

SIFI, an Italian ophthalmology company focused mostly on the European market, doesn’t normally make it out to San Francisco ...